Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1

Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1

Bibliographic Details
Main Authors:	Holland, A, Varela, M, Hazell, G, Klein, A, Arzumanov, A, Raz, R, Gait, M, Furling, D, Wood, M
Format:	Conference item
Language:	English
Published:	Elsevier 2018

Similar Items

PPMO's as therapeutic modulators for myotonic dystrophy type 1
by: Holland, A, et al.
Published: (2018)

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.
by: Betts, C, et al.
Published: (2012)

Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice
by: Klein, AF, et al.
Published: (2019)

Application of antisense conjugates for the treatment of myotonic dystrophy type 1
by: Stoodley, J, et al.
Published: (2023)

Peptide-conjugated PMOs for the treatment of myotonic dystrophy
by: Stoodley, J, et al.
Published: (2022)

NOVEL CELL PENETRATING PEPTIDES FOR SKELETAL AND CARDIAC MUSCLE DELIVERY OF PMO ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
by: Hammond, S, et al.
Published: (2011)

Proteomic analysis of the function of DMPK, the myotonic dystrophy protein kinase
by: Luciano, Brenda Sierra, 1965-
Published: (2005)

New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC).
by: Ashizawa, T, et al.
Published: (2000)

Application of CRISPR-Cas9-mediated genome editing for the treatment of myotonic dystrophy type 1
by: Marsh, S, et al.
Published: (2020)

Hearing impairment in patients with myotonic dystrophy type 2
by: van Vliet, J, et al.
Published: (2018)

The myotonic dystrophies: diagnosis and management.
by: Turner, C, et al.
Published: (2010)

Molecular genetics of myotonic dystrophy.
by: Barnes, P, et al.
Published: (1993)

Alternative isoform regulation in myotonic dystrophy
by: Wang, Eric T. (Eric Tzy-shi)
Published: (2012)

Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model
by: Overby, SJ, et al.
Published: (2022)

Myotonic dystrophy: diagnosis, management and new therapies.
by: Turner, C, et al.
Published: (2014)

Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1--the patients' perspective.
by: Hilton-Jones, D, et al.
Published: (2012)

Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1 - The patients' perspective
by: Hilton-Jones, D, et al.
Published: (2012)

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
by: Cerro-Herreros, E, et al.
Published: (2021)

Childhood-onset form of myotonic dystrophy type 1 and autism spectrum disorder: Is there comorbidity?
by: Angeard, N, et al.
Published: (2017)

Myotonic dystrophy--forgotten aspects of an often neglected condition.
by: Hilton-Jones, D
Published: (1997)

Clinical and molecular aspects of the myotonic dystrophies: a review.
by: Machuca-Tzili, L, et al.
Published: (2005)

Myotonic dystrophy: practical issues relating to assessment of strength.
by: Whittaker, R, et al.
Published: (2006)

Choroidal new vessels in type 1 myotonic dystrophy-related macular dystrophy respond to anti-VEGF therapy.
by: Zinkernagel, MS, et al.
Published: (2012)

Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy.
by: Talbot, K, et al.
Published: (2003)

Late-onset cytoplasmic body myopathy resembling myotonic dystrophy.
by: Morris, H, et al.
Published: (1999)

Three cases of androgen-dependent disease associated with myotonic dystrophy.
by: Cooper, S, et al.
Published: (2003)

Positive effect of modafinil on daytime somnolence on patients with Myotonic Dystrophy
by: Talbot, K, et al.
Published: (2002)

Preclinical development of antisense conjugates for the treatment of myotonic dystrophy 1
by: Stoodley, J
Published: (2024)

Downregulation of the Glial GLT1 glutamate transporter and purkinje cell dysfunction in a mouse model of myotonic dystrophy
by: Sicot, G, et al.
Published: (2017)

Advancing the potential of peptide-PMO compounds in exon skipping therapy for DMD
by: Godfrey, C, et al.
Published: (2012)

Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.
by: Yin, H, et al.
Published: (2011)

Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice
by: Yin, H, et al.
Published: (2011)

A randomised controlled trial of modafinil for treatment of daytime somnolence in myotonic dystrophy
by: Talbot, K, et al.
Published: (2003)

Using digital technologies to engage with medical research: views of myotonic dystrophy patients in Japan
by: Coathup, V, et al.
Published: (2016)

Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy
by: Wagner, Stacey D., et al.
Published: (2017)

Incorrect diagnosis of myotonic dystrophy and its potential consequences revealed by subsequent direct genetic analysis.
by: Barnes, P, et al.
Published: (1994)

Relationship between muscle impairments, postural stability, and gait parameters assessed with lower-trunk accelerometry in myotonic dystrophy type 1
by: Bachasson, D, et al.
Published: (2016)

DMPK and myotonic dystrophy : effects of CTG trinucleotide expansion upon DMPK and their contribution to DM pathogenesis
by: Davis, Brigid Michele, 1967-
Published: (2009)

The PMO theory of organic chemistry /
by: 291716 Dewar, Michael James Steuart, et al.
Published: (1975)

Does cytosine-thymine-guanine (CTG) expansion size predict cardiac events and electrocardiographic progression in myotonic dystrophy?
by: Clarke, N, et al.
Published: (2001)